Ask a scientific question
Start with a question.
Synthia handles the rest.
AI-driven insights for drug discovery and precision oncology.
Clinical Trials
Biomarkers
Mechanism
Literature
Protein Interactions
Resistance
Pathway Analysis
RMC-9805
92% evidence support
Research hypothesis — requires experimental validation
Refining evidence
312K pathways narrow to 24 candidates, then one strategy.
Filtering and prioritizing evidence…
Recommendation generated
From 41.7M evidence points to one therapeutic strategy.
312K pathways → 24 candidates → RMC-9805
Evidence considered
41.7M
data points
Pathways evaluated
312K
signaling pathways
Candidates considered
24
treatment strategies
Evidence support
92%
Literature · pathways · trials · resistance
Research hypothesis — requires experimental validation · not a clinical recommendation
Funnel preserved
41.7M → 312K → 24 → 1
Evidence-linked
Every claim traces to sources
Actionable output
One strategy, with the why
Therapeutic Rationale
RMC-9805 is a selective KRAS G12D inhibitor with preclinical efficacy in colorectal cancer models. Strong on-target activity with a favorable safety profile.
Key Mechanism
RMC-9805 selectively targets KRAS G12D, preventing downstream MAPK pathway activation and tumor cell proliferation.
Evidence considered
41.7M
data points
Pathways evaluated
312K
signaling pathways
Candidates considered
24
treatment strategies
Evidence support
92%
literature · pathways · trials · resistance
Top Supporting Evidence
3 of 28 sourcesMutant-selective KRAS G12D inhibition in colorectal models
Preclinical96%Adaptive MAPK feedback following KRAS pathway blockade
Mechanism92%Biomarker stratification in KRAS G12D colorectal cancer
Clinical84%Our AI-driven analysis
41.7M
biomedical evidence points analyzed across publications, datasets, and clinical sources
312K
signaling pathways evaluated
24
treatment strategies considered
1
evidence-backed therapeutic strategy recommended